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Protein aggregation takes place in many neurodegenerative disorders. However, there is a controversy about the possible toxicity
of these protein aggregates. In this review, this controversy is discussed, focussing on the tau aggregation that takes place in those
disorders known as tauopathies.
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INTRODUCTION
Many neurodegenerative disorders are characterized by their
presence in neural tissue of aberrant protein aggregates (see
Table 1). In general, these aggregates arise after the modiﬁ-
cation of a native protein. That modiﬁcation could result in
a conformational change of the native protein that promotes
the aberrant aggregation.
The most studied model of this mechanism has been
the prion protein where a change from an alpha helix to
beta sheet structure facilitates the polymerization of a pro-
tein with a diﬀerent conformation that appears to have a cy-
totoxic eﬀect [1].
In a similar way, conformational changes between a na-
tive protein and its aberrant protein counterpart with capac-
ity for self-assembly have been studied in many neurode-
generative diseases. Among the most common techniques
used for these analyses are X-ray diﬀraction, nuclear mag-
netic resonance, circular dichroism, or Fourier-transformed
infrared spectroscopy. Similarly, to the case of prion protein,
in some disorders a change from alpha helix to beta sheet
conformation has been suggested to cause protein aggrega-
tion (Table 1), probably because in alpha helix, intramolecu-
lar hydrogen bonds could occur whereas intramolecular hy-
drogen bonds are facilitated in beta sheet conformation, fa-
cilitating protein aggregation. However, there is one case, the
formation of aberrant aggregates of tau, where the aggre-
gated protein contains also a high proportion of alpha helix
structure [2].
Although, in some cases, like that of prion protein, the
formation of aberrant aggregates of protein could result in
at o x i ce ﬀect in the aﬀected neurons [1], in other cases, like
huntingtin aggregates, the formation of the aberrant aggre-
gatescouldbeasurvivalresponseoftheaﬀectedneurons[3].
In other neurodegenerative diseases, it will be of interest to
know if protein aggregation is synonymous of cell toxicity or
not.
Protein conformation could also play a role in a possi-
ble toxic mechanism. In this way, a protein with a high pro-
portion of alpha helix and hydrophobic regions could be in-
serted in cell membrane promoting toxic eﬀects [4]. Addi-
tionally, the presence of aberrant polymers could aﬀect the
protein degradation cell machinery (the proteasome com-
plex), decreasing its activity and promoting a toxic eﬀect
[5].
Recently,somegoodreviewshavebeenpublishedonpro-
tein aggregation and neurodegenerative disorders [6, 7]. In
this review we will mainly focus on those aggregates assem-
bled from tau protein, aggregates that could be present in the
neurologicaldisordersknownastauopathies(forareviewsee
[8]) (Table 1).
TAU AGGREGATION
It has been described that large amounts of native or un-
modiﬁed tau protein were enough to promote tau assembly
into ﬁbrillar polymers resembling those found in AD [9–12].
Thus, obviously, an increase in tau concentration will favour
the formation of tau polymers. Recently, it has been reported
that not all the brain areas have a similar amount of tau pro-
tein [13]. Thus, it suggests a diﬀerent probability in the for-
mation of tau polymers in diﬀerent brain regions.
The amount of tau will be the consequence of its syn-
thesis and its degradation. Changes in transcription have2 Journal of Biomedicine and Biotechnology
Table 1: Examples of neurological diseases where aberrant protein aggregates are found, and the suggested conformations in the aberrant
aggregates are indicated.
Proteinopathies (aberrant aggregation)
Disease Protein Pathological ﬁnding Protein conformation
Prion diseases PrPSc PrP amyloid plaques β-sheet
Alzheimer’s disease
Aβ Aβ amyloid plaques β-sheet
Tau Paired helical ﬁlaments β-sheet + α-helix
in neuroﬁbrillary tangles
Parkinson’s disease α-synuclein Lewy bodies β-sheet + α-helix
Frontotemporal dementia Tau Straight ﬁlaments —–
and paired helical ﬁlaments
Pick’s disease Tau Pick bodies —–
Progressive supranuclear palsy Tau Straight ﬁlaments is neurﬁbrillary tangles —–
Amyotrophic lateral sclerosis Neuroﬁlament Neural aggregates —–
Huntington’s disease Huntingtin Nuclear inclusions β-sheet
Spinocerebellar ataxia
Type 1 Ataxin 1 Nuclear inclusions β-sheet
Type 2 Ataxin 2 Cytoplasmic inclusions β-sheet
Machado-Joseph disease Ataxin 3 Nuclear inclusions β-sheet
been indicated for other proteins related to neurodegener-
ative disorders [14], where a TATA binding protein may play
a role. Tau degradation may take place through the protea-
some complex [15, 16] and it has been suggested that such
degradation could be regulated by posttranslational modiﬁ-
cations occurring in tau molecule, like its phosphorylation
[17]. Also, tau degradation by other proteases could be reg-
ulated by its level of phosphorylation [18]. It should be also
indicatedthatinsomecaseslikeParkinson’sdiseaseorLafora
disease, mutations in the E3 ubiquitin ligases like parkin [19]
or malin [20] will result in the appearance of aberrant pro-
tein aggregates.
Aconformationalchange, that couldbe followedby anti-
bodies thatreactwithtau moleculeafterthatconformational
change [21–24]hasbeenalsosuggestedtoberequiredforthe
transition tau monomer-tau polymer.
Also,ithasbeensuggestedthatdiﬀerentposttranslational
modiﬁcations like phosphorylation [25], glycation [26], or
truncation[27], may play a role in the formation of tau poly-
mers.
Duetothealternativesplicingofitsheterogenous(ornu-
clear) RNA, diﬀerent tau isoforms could be expressed and,
therefore, diﬀerent tau aggregates with diﬀerent tau isoforms
in diﬀerent tauopathies could occur, but we will not discuss
this point here. For further information see [8].
Mainly, studies on phosphorylation and truncation have
been done. About truncation, it has been suggested that re-
moval of the amino and/or carboxy terminal regions, leaving
the tubulin binding region will facilitate tau polymerization
[21, 22, 28].
Some work has been done in vitro [29] and in vivo
[30, 31] about a possible role of tau phosphorylation on tau
assembly, suggesting that in some conditions tau phosphory-
lation may increase the capacity of tau for its self-assembly.
Not only an increase in serine/threonine phosphorylation of
tau could regulate its aggregation but also an increase in tau
tyrosine phosphorylation may increase the formation of tau
aggregates [32]. This assembly process may involve the for-
mation of oligomers [33], ﬁlaments, and aggregates of ﬁla-
ments (tangle-like structures). In the formation of these ag-
gregates of ﬁlaments, glycation may play a role [26].
The possible relation between phosphorylation and tau
aggregation has been studied in transgenic mice express-
ing human tau bearing some mutations found in human
fronto-temporal dementia linked to chromosome 17 (FTDP-
17) [31]. In this mouse, tau phosphorylation mainly oc-
curs by GSK3 [34]. When a speciﬁc inhibitor of this kinase,
lithium, was given to the transgenic mice no tau phosphory-
lation was found, and in addition no aggregation of the pro-
tein was detected [31] suggesting a correlation between tau
phosphorylation and aggregation in this model. This result
was supported by an additional experiment using another
mouse also expressing human tau with a FTDP-17 mutation
[30].
Alternatively, protein chaperones, acting on tau or in
phosphotau, could modify the level of tau aggregation, ex-
amples could be the protein 14-3-3 [35], musashi-1 [36],
or Pin-1 [37, 38]. The chaperone associated ubiquitin ligase
CHIP could be able to target phosphotau for proteasomal
degradation [16, 18].J. Avila et al 3
TOXICITY OF PHOSPHOTAU
It has been described that tau binding to microtubules is reg-
ulated by the level of tau phosphorylation at some speciﬁc
sites [39]. It is known that hyperphosphorylated tau binds
with less aﬃnity to microtubules resulting in the decrease in
the interaction with microtubules, in a decrease of micro-
tubule stability [8], and probably in a microtubule dysfunc-
tioninsidethecellthatcouldresultinatoxiceﬀect[40].Also,
tau phosphorylation could result, as indicated above, in a de-
crease of its proteolysis [17]. More recently, it has been indi-
cated that expression of a tau mutant (P301L) could result
in an increase of its phosphorylation, since once it is phos-
phorylated, that mutation can prevent the binding of those
phosphatases involved in its dephosphorylation [41]. This
phosphotau could have a decreased capacity for microtubule
binding and it could be toxic for the cell. Additionally, it has
been indicated that hyperphosphorylated tau can cause neu-
rodegeneration, in the absence of large tau aggregates [42].
On the other hand, only the overexpression of wild-type hu-
man tau in a mouse is suﬃcient to cause tau phosphory-
lation, aggregation, and neural toxicity [43]. On the other
hand, it has been suggested that tau phosphorylation may
represent a protective function in AD [44].
TOXICITY OF AGGREGATED TAU
Sometime ago, the development of tau pathology, related
with dementia in AD [45], was clearly described by Braak
and Braak [46] by following the development of neuroﬁb-
rillary lesions at diﬀerent stages of the disease. Also, the for-
mation of neuroﬁbrillary (tau aggregates) pathology within
those neurons of hippocampus and cerebral cortex aﬀected
at diﬀerent stages was found. These neurons could degener-
ate yielding extracellular ghost tangles (eNFT) [47]. In the
hippocampus, an inverse relation has been found between
the number of eNFT and the number of surviving neurons
[48–51]. It suggests that neurons that degenerate, have pre-
viously developed tau aggregates. On the other hand, it has
been indicated that neurons bearing neuroﬁbrillary lesions
could survive for a long period of time [52], and, by compar-
ing with other neurodegenerative disorders, like Huntington
disease [3], it can be suggested that tau aggregates could pro-
tect against neurodegeneration by sequestering toxic (phos-
pho?)monomerictauthatcouldbepresentinahighamount
inside a cell in pathological conditions. Also, it has been
suggested, using a transgenic mouse model [53], that be-
havioural (memory) deﬁcits could be unrelated to the for-
mation of tau polymers, although, more recently, the discus-
sion of those experiments suggested that hyperphosphory-
lated, aggregated tau intermediates could be the ones that
cause neurodegeneration [33]. In this way, the implication
of diﬀerent types of protein aggregates in neurodegeneration
has been extensively discussed [19, 54]. A possibility about
the existence of neurotoxic tau intermediate aggregates in
human tauopathies is based in the fact that patients with
FTDP-17 show an extensive neurodegeneration with a high
level of tau phosphorylation but with a low number of tan-
gles [55].
In any case, even if the formation of tau aggregates has
a protective function for the neurons, that function is not
working well, as described by Braak and Braak [46], and af-
terwards by Delacourte et al [56],indicatingacorrelationbe-
tween progression of tau pathology and progression of the
disease. This idea is supported by those experiments indicat-
ing that neural loss and neuroﬁbrillary tangle number in-
crease in parallel with the progression of the disease [57].
Similar results have been described in other neurological dis-
orders like brain encelphalopathies, where the formation of
aberrant polymers are related to the onset of neurodegenera-
tion [1]; whereas this is far from clear in other disorders like
Huntington disease.
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